Figure 3.

C1M levels in PBO + MTX or TCZ + MTX treated patients. A: Percentage change in C1M levels from baseline in all patients (including patients, who received TCZ). TCZ4, TCZ 4 mg/kg. TCZ8, TCZ 8 mg/kg. B: C1M levels in the subpopulations of the PBO group. Non-escape Week 16 n = 86, escape Week 16 n = 81. Non-escape Week 24 n = 79, escape Week 24 n = 78, non-escape Week 52 n = 66, escape Week 52 n = 56. Values are depicted as mean + SEM. Two-way ANOVA test was used to test for differences. Significant levels: *: P <0.05, **: P <0.01, ****: P <0.0001. C1M, Type I collagen degraded by MMPs; MTX, methotrexate; PBO, placebo; TCZ, tocilizumab

Siebuhr et al. Arthritis Research & Therapy 2013 15:R86   doi:10.1186/ar4266
Download authors' original image